Filter by: patients
Home > Community Treatment Reports and Side Effects > Parkinson's Phase 3 Study Safinimide Treatment Report
What is Parkinson's Phase 3 Study Safinimide?

NCT01187966 is a double-blind, placebo-controlled study to determine the efficacy and safety of a low and high dose of safinamide, as add-on therapy, in patients with idiopathic Parkinson's disease with motor fluctuations, treated with levodopa. Other study ID: NW-1015/016/III/2006.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Parkinson's Disease 1 1 Efficacy_none

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 1
Mild
 0
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Parkinson's Phase 3 Study Safinimide

Moodiness 1

Reported Stop Reasons

Why Patients Stopped Using Parkinson's Phase 3 Study Safinimide (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 1   Doctor's advice: 100%

See all 1 patient who’ve stopped using Parkinson's Phase 3 Study Safinimide

Reported Duration See details about how long patients take this treatment ▼

Stopped Using Parkinson's Phase 3 Study Safinimide

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Parkinson's Phase 3 Study Safinimide

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Parkinson's Phase 3 Study Safinimide

Very
 0 0%
Somewhat
 1 100%
A little
 0 0%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Parkinson's Phase 3 Study Safinimide

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 26, 2012.